Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MC4R | P32245 | 2/20 | 0.42 |
| ▸ | MC3R | P41968 | 2/20 | 0.42 |
| ▸ | MC1R | Q01726 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 2/20 | 0.42 |
| ▸ | GPR183 | P32249 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | IL6ST | P40189 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5877892 | 1.00 | ALDH1A1 (0.46) | ALDH1A1HPGDHTTLMNAMAPT | |
| SCHEMBL3658644 | 1.00 | ALDH1A1 (0.46) | ALDH1A1HPGDHTTLMNAMAPT | |
| SCHEMBL1915646 | 0.92 | NAAA (0.47) | ALDH1A1HPGDMC4RMC3RMC1R | |
| SCHEMBL7346791 | 0.92 | NAAA (0.47) | ALDH1A1HPGDMC4RMC3RMC1R | |
| SCHEMBL1915643 | 0.92 | NAAA (0.47) | ALDH1A1HPGDMC4RMC3RMC1R | |
| SCHEMBL16307020 | 0.88 | KDM4E (0.44) | MC4RMC3RMC1RNAAAFAAH | |
| SCHEMBL13494502 | 0.88 | KDM4E (0.44) | MC4RMC3RMC1RNAAAFAAH | |
| SCHEMBL1919141 | 0.88 | KDM4E (0.44) | MC4RMC3RMC1RNAAAFAAH | |
| SCHEMBL6788947 | 0.88 | NAAA (0.51) | NAAAFAAHNPC1EP300CARM1 | |
| SCHEMBL23866771 | 0.88 | NAAA (0.51) | ALDH1A1HPGDLMNAMC4RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110218182-B | IDO inhibitors | 南京亘泰医药技术有限公司 | 2021-01-26 | — | — | CN | disclosed |
| EP-3283062-A1 | HYDROXAMIC ACIDS AND USES THEREOF | Hawaii Biotech, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9688618-B2 | Hydroxamic acids and uses thereof | HAWAII BIOTECH, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170036996-A1 | HYDROXAMIC ACIDS AND USES THEREOF | HAWAII BIOTECH, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9505710-B2 | Hydroxamic acids and uses thereof | HAWAII BIOTECH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| WO-2016168483-A1 | HYDROXAMIC ACIDS AND USES THEREOF | HAWAII BIOTECH, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304443-A1 | HYDROXAMIC ACIDS AND USES THEREOF | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-10-20 | — | — | US | disclosed |
| US-8841304-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8372842-B2 | Pyrazolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-6596716-B2 | 2-propane-sulphonamide derivatives | ELI LILLY AND COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-6525099-B1 | Potentiating glutamate receptor function; psychiatric and neurological disorders | ELI LILLY AND COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6521605-B1 | Potentiating glutamate receptor function; treating such as psychiatric and neurological disorders | ELI LILLY AND COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-20020002158-A1 | Sulphonamide derivatives | ARNOLD MACKLIN B (US) | 2002-01-03 | — | — | US | disclosed |
| US-6303816-B1 | Sulphonamide derivatives | ELI LILLY AND COMPANY | 2001-10-16 | — | — | US | disclosed |
| WO-2000006537-A1 | N-SUBSTITUTED SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006176-A1 | AMIDOPHOSPHATE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0976744-A1 | Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0860428-A2 | Sulphonamide derivatives | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1998033496-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002158-A1 | Sulphonamide derivatives | GRIN2C, GRM1, GRM3 | ALDH1A1 655/4885HPGD 3090/4885HTT 3147/4885 |
| US-20140221370-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | ALDH1A1 2477/4885HPGD 1153/4885HTT 4380/4885 |
| US-20160304443-A1 | HYDROXAMIC ACIDS AND USES THEREOF | HRH3, H1-3, H1-0 | ALDH1A1 2944/4885HPGD 317/4885HTT 1130/4885 |
| US-20170036996-A1 | HYDROXAMIC ACIDS AND USES THEREOF | HRH3, H1-3, H1-0 | ALDH1A1 2944/4885HPGD 317/4885HTT 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.